| |
HEARTWARE LIMITED Company Summary |
|
HeartWare is developing a family of proprietary circulatory assist devices to treat patients with congestive heart failure. HeartWare's lead device, the HVAD, commenced human clinical trials in March 2006. First sales are anticipated in late 2007. With a volume of 45cc, the HVAD is the smallest "3rd generation" pump and the only full output device implantable within the pericardial space.
In parallel with the HVAD clinical development, HeartWare is pursuing its MVAD program, aimed at developing a family of miniaturized cardiac assist devices, implantable by minimally invasive surgical techniques. The current MVAD prototype, approximately one tenth the volume of the HVAD, commenced animal studies in August 2005.
HeartWare listed on the Australian Stock Exchange (ASX: HTW) on 31 January 2005 after successfully raising A$32.4 million (US$24.95 million). HeartWare's Head Office is located in Sydney, Australia. |
|
|
|
 |
Headquarters |
Suite 2, Level 46, 2 Park Street SYDNEY NSW 2000 |
 |
|
Telephone |
+61 2 8215 7600 |
|
|
Fax |
+61 2 8215 7650 |
|
|
Principal Sector |
Health & Pharm |
|
|
Principal Industry |
Healthcare |
|
|
Listed |
31 Jan 2005 |
|
|
Homepage |
www.heartware.com |
|
| |
|
|
|
|
| |
NEWS |
 |
|
|  Heartware Announce Clinical Trial Update (JULY 13, 2007) | | Heartware Delivers Australian Presentation on HVAD Implants (JUNE 15, 2006) | | Heartware Annual General Meeting Presentation May 23, 2006 (MAY 23, 2006) | | HeartWare Receives Regulatory Approval For HVAD Implants in the UK (MAY 22, 2006) | | HeartWare Ltd Offers Shareholders Discounted Shares on ASX (MAY 19, 2006) | | HeartWare Announce $32.5 Million Capital Raising (MAY 10, 2006) | | HeartWare Appoints COO to Florida Operations Centre (APR 21, 2006) | | First Human Implant of HeartWare's HVAD (MAR 24, 2006) | | Heartware Gets Regulatory Approval in Europe for Human Implants (JAN 5, 2006) | | Ventracor and Heartware make agreement on Intellectual Property Issues (NOV 10, 2005) |
|
|
|
|
